Navigation Links
Aethlon Medical Announces Approval and Initiation of Cancer Research Study to Target Tumor-Secreted Exosomes

SAN DIEGO, Dec. 6, 2011 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that a cancer research study to test the ex vivo effectiveness of the Aethlon Hemopurifier® to capture tumor-secreted exosomes from the blood of advanced-stage cancer patients has received institutional review board approval to begin studies at the Sarcoma Oncology Center, based in Santa Monica, California. The study will enroll up to 25 patients with metastatic cancer, including those with non-small cell lung cancer, prostate cancer, melanoma, head and neck cancer, and sarcoma.  Testing of blood samples provided by three enrolled sarcoma patients has already been initiated.  The study goal is to establish the first validation that a medical device, the Aethlon Hemopurifier®, can effectively capture tumor-secreted exosomes from the blood of cancer patients.  Successful study outcomes would provide a basis for follow-on human treatment studies in cancer patients.


Tumor-secreted exosomes, which are not addressed by drug therapy, assist cancerous tumors in evading the immune response and are implicated in the survival, growth, and metastasis of cancer.  The Aethlon Hemopurifier® is a first-in-class medical device with broad-spectrum capabilities against viral pathogens, including HIV and Hepatitis C virus (HCV).  The device has also demonstrated the ability to capture tumor-secreted exosomes from cell culture and human ascites fluids.  At present, the Hemopurifier® is being evaluated in human studies as an adjunct therapy to improve outcomes of HCV patients receiving interferon therapy.

The Sarcoma Oncology Center is a highly sought after research center for the clinical testing of new therapeutic candidates against sarcomas and other forms of cancer. Dr. Sant Chawla, the lead investigator of the study is a recognized authority in the sarcoma oncology field.

About Aethlon Medical

The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.  Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the Hemopurifier's® ability to capture tumor-secreted  exosomes and the impact it may have on disease conditions, the ability to successfully complete the Medanta HCV study and achieve positive results, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.

James A. Joyce
Chairman and CEO
858.459.7800 x301

Jody Cain
Senior Vice President, Lippert/Heilshorn & Associates

Jim Frakes
Chief Financial Officer
858.459.7800 x300

John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307

SOURCE Aethlon Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Aethlon Medical Releases Shareholder Letter
2. Aethlon Medical to Present at IN3 Medical Innovation Summit on October 27th
3. Aethlon Medical Announces Availability of its Exosome Detection Assay to the Research Community
4. Aethlon Medical Announces Hemopurifier® and HER2osome™ Cancer Therapy Presentation at Exosomes and Microvesicles 2011
5. "A Medical Device Strategy To Inhibit HER2+ Breast Cancer Progression" Released by Aethlon Medical, Inc.
6. Aethlon Medical Introduces HER2osome™, A Novel Therapeutic Device Strategy to Address Breast Cancer
7. Aethlon Medical Releases Shareholder Letter
8. Aethlon Medical to Discuss Recent Progress at the LHA Life Sciences & Medical Technologies Virtual Conference on June 16
9. Aethlon Medical to Present the Aethlon ADAPT™ System at C21 BioVentures™ Life Sciences Partnering Conference
10. Aethlon Medical Clarifies News Report
11. ABC News Reports on Aethlon Medical
Post Your Comments:
(Date:11/24/2015)... The hope of bearing a ... IVF cycles. After failure of over 15 IVF cycles, ... all hopes that she would be able to conceive ever. But finally optimism prevailed as ... failure of over 15 IVF cycles. ... take one last attempt with Gaudium IVF Center in ...
(Date:11/24/2015)... CARLOS, Calif. , Nov. 24, 2015 ... a leader in non-invasive genetic testing and ... announced that it will present at the ... in New York on Wednesday, December 2, 2015 at 1:00 p.m. ET.  Matthew ... the Company,s financial results, business activities and ...
(Date:11/24/2015)... 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the ... that the first patient has been enrolled in ESSA,s ... for metastatic castration-resistant prostate cancer ("mCRPC"). ... --> the United States and ... clinical trial, ESSA intends to demonstrate the safety, tolerability, ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... 24, 2015 , ... In response to recent news highlighting Oxycodone fraud, Novus ... in the United States grew 400 percent between 1999 and 2010, far more than ... 37 percent of all fatal drug overdoses. (1) , While oxycodone and the extended ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Serenity Point ... a series of recent video interviews with some of the staff members at their ... the residential treatment facility, as well as some of the things that make their ...
(Date:11/24/2015)... ... 2015 , ... Chiropractic student Katie Benson received a $2,500 ... Park, Kansas. Benson, a fifth-trimester student in the university’s College of Chiropractic, accepted ... 16. , “Katie is very excited and greatly appreciative to receive the Standard ...
(Date:11/24/2015)... ... November 24, 2015 , ... Autism Speaks, the world’s leading autism science and ... media and the generosity of people around the world. On December 1, supporters can ... give – and share the personal stories behind those gifts. , Just as ...
(Date:11/24/2015)... ... November 24, 2015 , ... World ... Fragrance by Marcelle, a cosmetic invention which offers a combination of natural essential ... in the US is worth $3 billion annually," says Scott Cooper, CEO and ...
Breaking Medicine News(10 mins):